Across the four main semaglutide weight-loss trials, more than 3,300 adults filled out a standard depression questionnaire (the PHQ-9) for over a year. People on semaglutide were less likely than people on placebo to move into a more severe depression category (odds ratio 0.63), and rates of suicidal thoughts or behavior were 1% or less, with no difference between groups (Wadden et al., JAMA Internal Medicine, 2024, DOI (external link)). That result, repeated across tens of thousands of trial participants, is why regulators now say GLP-1 medications don't raise the risk of depression or suicidal thinking. It isn't the whole story, though. If you live with depression, or worry about developing it, the unsettled parts matter too.
If you are thinking about harming yourself right now: call or text 988 (Suicide & Crisis Lifeline, US), text HOME to 741741 (Crisis Text Line), or call 911. Outside the US, call your local emergency number. You don't need to work out whether a medication is involved before asking for help.
Why the question keeps coming up
Obesity and depression feed each other. A meta-analysis of 15 long-term studies found that obesity at baseline raised the odds of later depression (odds ratio 1.55), and depression raised the odds of later obesity (1.58) (Luppino et al., Archives of General Psychiatry, 2010, DOI (external link)). So many people starting a GLP-1 already carry a higher background risk of depression. Some will develop depression while on the drug whether or not the drug plays any part. Telling those cases apart from a true drug effect is the whole challenge.
Two more things kept the question alive. In July 2023, reports from Iceland of suicidal thoughts on liraglutide and semaglutide led the European Medicines Agency to open a formal safety review (EMA statement, July 11, 2023 (external link)). It closed in April 2024, as described below. And these drugs act on the brain's appetite and reward circuits, which raised a plausible concern that dampening "food reward" might dampen other pleasures too. That concern, called anhedonia, has its own guide: mood changes and anhedonia on a GLP-1. This article focuses on depression.
The evidence that raises concern
The worrying signals are real:
- In the WHO's global adverse-event database, semaglutide carried reporting signals for depressed mood (adjusted reporting odds ratio 1.70) and suicidality (1.45). GLP-1s overall did not show a rise in psychiatric reports, and no signals appeared in data from before June 2021, when semaglutide was approved for weight loss (Nishida et al., Clinical Nutrition, 2025, DOI (external link)). These are voluntary reports. Media coverage can drive them, and they can't show how often something happens or whether the drug caused it.
- Across 13 South Korean hospitals, adults starting semaglutide for weight loss had higher recorded rates of depressive disorder than matched people who didn't start a GLP-1 (hazard ratio 3.42, with a wide 95% confidence interval of 1.51–7.74). Liraglutide showed a smaller increase (1.51) (Park et al., Diabetes, Obesity and Metabolism, 2026, DOI (external link)). People who start a weight-loss drug see doctors more often and may differ in ways matching can't fully remove, so this comparison is prone to bias. It is still a signal.
- In six US health systems, sustained GLP-1 use in type 2 diabetes was linked to about 1 extra depression diagnosis per 100 people over 2.5 years compared with SGLT2 inhibitors, and about 1.8 per 100 compared with sulfonylureas. There was no difference compared with DPP-4 inhibitors (Hooker et al., Diabetes, Obesity and Metabolism, 2026, DOI (external link)).
The evidence that reassures
The strongest designs point the other way:
- In the semaglutide trials STEP 1, 2, 3 and 5, semaglutide 2.4 mg lowered depression scores slightly compared with placebo (a 0.56-point difference on a 27-point scale, which the authors judged not clinically meaningful). It also lowered the chance of worsening into a more severe category, with no difference in suicidal thoughts or behavior (Wadden et al., JAMA Internal Medicine, 2024, DOI (external link)).
- Across the tirzepatide trials SURMOUNT-1, -2 and -3 (4,056 participants), fewer people on tirzepatide than on placebo shifted to a more severe depression category (18.2% vs. 24.3%). Suicidal ideation was reported by 0.6% in both groups (Wadden et al., Obesity, 2026, DOI (external link)).
- Pooling 86 randomized trials and 133,378 participants, GLP-1 drugs were not associated with depression (risk ratio 0.88, 95% CI 0.70–1.10), suicide, or anxiety, and results held across drug, dose, duration and indication (Han et al., Diabetes, Obesity and Metabolism, 2026, DOI (external link)).
- On January 13, 2026, the FDA reported a meta-analysis of 91 placebo-controlled trials with 107,910 patients that found no increased risk of suicidal ideation or behavior "or for other relevant psychiatric adverse events." The agency asked manufacturers to remove the suicidal behavior and ideation warning from the Saxenda, Wegovy and Zepbound labels. As of September 2026, the Wegovy prescribing information on DailyMed lists that warning as removed in February 2026. Check the current label for the others.
- In April 2024, the EMA's safety committee concluded that the evidence does not support a causal link between GLP-1 receptor agonists and suicidal or self-injurious thoughts and actions.
- In 240,618 people with overweight or obesity, semaglutide was associated with a lower risk of new suicidal ideation than other weight-loss medications (hazard ratio 0.27) (Wang et al., Nature Medicine, 2024, DOI (external link)).
Why the studies disagree
Much of the disagreement comes down to what the drug is compared with. In a Korean national study of people with type 2 diabetes, GLP-1 users had the same depression risk as DPP-4 inhibitor users (hazard ratio 1.00) but a higher risk than SGLT2 inhibitor users (1.20) (Kim et al., Diabetes, Obesity and Metabolism, 2026, DOI (external link)). In the US study above, SGLT2 inhibitors were themselves linked to less depression than DPP-4 inhibitors. So a "GLP-1 vs. SGLT2" gap may partly reflect SGLT2 drugs looking good, and not only GLP-1s looking bad. Comparisons with "people who didn't start any drug" carry the most room for bias.
Trials have a different limit: most excluded people with major psychiatric illness. The tirzepatide authors say further study in people with significant psychiatric illness may be warranted. So the trial reassurance is strongest for people without a serious psychiatric history.
If you already have depression
Having depression doesn't automatically rule out a GLP-1. In a US study of 34,761 matched pairs of adults with type 2 diabetes and treated depression, starting a GLP-1 did not raise documented suicidality compared with starting an SGLT2 inhibitor (hazard ratio 0.88, not statistically significant). It was linked to less later escalation to antipsychotic medication. The authors conclude that treated depression alone should not lead to routine avoidance of these drugs (Chang et al., Diabetes, Obesity and Metabolism, 2026, DOI (external link)). That study was observational and limited to type 2 diabetes. Practical steps:
- Keep your mental-health treatment going. Don't stop an antidepressant or therapy because you've started a GLP-1.
- Make sure both prescribers know. Your GLP-1 prescriber should know your psychiatric history, and your mental-health clinician should know you've started a GLP-1.
- Agree on a plan in advance: what changes would make you call, and whom.
Is a GLP-1 a treatment for depression?
No. A 2026 meta-analysis of randomized trials found a small improvement in general psychological well-being, but no significant effect on depressive symptoms (11 trials, 1,961 participants). The authors suggest any benefit probably comes indirectly, through better metabolic health, and not from a direct antidepressant effect (Hung et al., Human Psychopharmacology, 2026, DOI (external link)). Feeling better as your health improves is real, but it is not a reason to start a GLP-1 for depression or to drop treatment that works.
Stopping can matter too
One question is newer: what happens to mood after the drug stops? In a large Shanghai health-records study of people with type 2 diabetes, GLP-1s were neutral or better than comparison drugs for new depression and anxiety during treatment. After stopping, prior GLP-1 users had a higher risk than people who had stopped DPP-4 or SGLT2 inhibitors (Zhang et al., Nature Metabolism, 2026, DOI (external link)). It is a single observational study, but it's reason enough to plan a stop with your prescriber and keep watching your mood for the months afterward. Returning appetite and weight regain can be hard emotionally in their own right.
What to watch, and when to act
You can't predict which way your mood will go, so watch it deliberately:
- Know the core signs of depression: low mood or loss of interest or pleasure most days for two weeks or more, plus changes such as hopelessness, poor sleep, low energy, trouble concentrating, or feeling worthless. Appetite loss is expected on a GLP-1, so it tells you little here. Loss of interest in non-food things you used to enjoy tells you more.
- Keep a one-line daily mood note. A trend is easier to spot and easier to describe to a clinician.
- Check the physical contributors. Under-eating, poor sleep, dehydration and nutrient shortfalls can cause fatigue and flatness that look like low mood. Our labs-first micronutrient guide covers which blood tests to ask about.
- Tell your prescriber about new or worsening depression promptly. The FDA's advice to patients hasn't changed with the label: tell your health care professional about "new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior."
- Get support for the emotional side of change. Body change, shifting relationships and health worry are real stressors. Our guide to getting mental health support on a GLP-1 covers finding and paying for a therapist. If worry is more your pattern than low mood, see GLP-1 medications and anxiety.
- Thoughts of suicide or self-harm are an emergency, whatever the cause: call or text 988, text HOME to 741741, or call 911.
The bottom line
For most people, a GLP-1 is neither a depression treatment nor a depression trigger. The open questions sit with people who have serious psychiatric illness, whom the trials mostly left out, and with the months after stopping. Keep your mental-health care going, watch your mood as carefully as your weight, and get help early.
This article is general education, not medical or mental-health advice, and it is not a crisis service. If you're in crisis, use the resources above. Discuss any mood changes with your prescriber or a licensed mental-health professional. Research findings above are attributed to PubMed-indexed articles with DOI links.